Breaking News

New questions about Epstein & a Harvard genetics study

March 5, 2026
admin-ajax
Morning Rounds Writer and Reporter

Good morning. There's a lot of disconcerting news about AI in journalism lately. So this is a reminder that all of STAT's journalism, including this newsletter, is reported and written by humans. (Which, yes, includes my spelling mistakes. It's Murakami, of course!)

exclusive

A new mystery about Epstein's involvement in Harvard genetics study

s3___bgmp-arc_arc-feeds_generic-photos_to-arc_WALKER_100325_Harvard_1484x-1600x900Craig F. Walker/The Boston Globe

Sex trafficker Jeffrey Epstein died in 2019. That's why it's so strange that somebody appears to have altered the Personal Genome Project's public profile page believed to belong to Epstein on Jan. 31, 2026. That's nearly thirteen years after Epstein initially expressed interest in joining the project, six years after he was found dead in a jail cell, and just one day after the latest tranche of investigation files were released by the Department of Justice.

STAT's Megan Molteni had previously reported that the whereabouts of Epstein's cells are unknown. Like a truly great sleuth, she then matched the time and date stamps in Epstein's released emails discussing his participation in the project with a participant profile whose enrollment history lined up. (The project is an experiment in radical research transparency, meaning everyone's profile is public, though most are anonymous.)

Read more from Megan on how the consent form could have been updated after Epstein's death, and what the program's leader, personal genomics pioneer George Church, had to say about it.


global health

Chile eliminates leprosy in WHO milestone

Chile has become the first country in the Americas and second country in the world to be officially verified by the World Health Organization and the Pan American Health Organization for eliminating leprosy. It's been more than 30 years since the country saw a locally acquired case of the bacterial infection, which can develop slowly over up to 20 years, manifesting as painless lesions or lumps on the skin.

Globally, there are about 200,000 new leprosy cases reported annually in more than 120 countries. Here in the U.S., cases of leprosy are rare, with locally acquired cases even more so. But there's evidence that the disease is on the rise in Florida and could become endemic. There were at least 36 cases reported in the state in 2025, as compared to 20 in 2024. (But take comfort: Leprosy does not spread easily, and it is curable with antibiotics. Doctors say there's no cause for alarm with the Florida cases.)


politics

TrumpRx offers limited number of drugs one month in

When President Trump launched his signature drug discount platform, he heralded it as "one of the most transformative health care initiatives of all time." But a month later, just a few dozen drugs are available, it's unclear how much the site is being used, and the private deals underlying TrumpRx are still being worked out.

"Some are going to benefit, and others — probably the majority — won't," Michelle Long, senior policy manager for KFF's Program on Patient and Consumer Protections, told STAT's Daniel Payne about TrumpRx. "Is it the greatest thing in the health care world? Clearly no." Read more from Daniel on what questions we're still asking about the platform.



chart it

Pediatric nicotine exposure shifts with trends

A chart showing that pediatric nicotine exposures via ingestion have decreased over recent years while inhalation/nasal exposures have increased.

JAMA Network Open 

Between 2016 and 2023, there were more than 92,900 reported instances of nicotine exposure for children between 1 month and 5 years old, per the National Poison Data System. (Exposure is defined as ingesting something like a pouch, or inhaling from a cigarette or vape, though it doesn't capture incidental exposure to secondhand smoke.) An analysis of that data, published yesterday in JAMA Network Open, found that the route of exposure has clearly changed over the years.

Exposure to e-cigarettes increased 243%, while exposure to traditional tobacco dropped by 43%, the study authors found. The trend coincides, they wrote, with a market shift toward disposable and cartridge-based vapes. (Follow STAT's reporting on vaping here.)


first opinion

Is evidence catching up with anecdotes about GLP-1s and addiction?

At least one expert seems to think so. In a new First Opinion essay, physician-researcher Ziyad Al-Aly writes about the results of a study by him and his colleagues, published yesterday in the BMJ. Among more than 600,000 people, they found that GLP-1 drugs were associated with 50% fewer substance-related deaths, 39% fewer drug overdoses, and 26% fewer drug-related hospitalizations.

"Drug noise is the signal these drugs appear to quiet — not for one substance, but for all of them," Al-Aly writes. But he acknowledges a key question: "Why would a drug designed for diabetes quiet drug noise?" Read more for his thoughts on the potential mechanisms.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Planned Parenthood wants you to get your Botox at its clinic, Wall Street Journal

  • RFK Jr. has wide discretion to choose evidence to support vaccine decisions, DOJ argues, STAT
  • Is RFK Jr. coming for your Dunkin? Boston Globe
  • First Opinion: AI could revolutionize antibiotics — but the market is standing in the way, STAT
  • What it's like to have a brain implant for five years, Wired

Thanks for reading! More next time,


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments